BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33461782)

  • 1. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.
    Motzer RJ; Russo P; Haas N; Doehn C; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Lim HY; Melichar B; Zemanova M; Rini B; Choueiri TK; Wood L; Reaume MN; Stenzl A; Chowdhury S; McDermott R; Michael A; Izquierdo M; Aimone P; Zhang H; Sternberg CN;
    Eur Urol; 2021 Mar; 79(3):334-338. PubMed ID: 33461782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8: PROTECTing Patients with Locally Advanced Kidney Cancer.
    Singla N; Pierorazio P; Allaf M; Ged Y
    Eur Urol; 2021 Jul; 80(1):e33-e34. PubMed ID: 33962807
    [No Abstract]   [Full Text] [Related]  

  • 5. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
    Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
    Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
    Sternberg CN; Davis ID; Mardiak J; Szczylik C; Lee E; Wagstaff J; Barrios CH; Salman P; Gladkov OA; Kavina A; Zarbá JJ; Chen M; McCann L; Pandite L; Roychowdhury DF; Hawkins RE
    J Clin Oncol; 2010 Feb; 28(6):1061-8. PubMed ID: 20100962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.
    Appleman LJ; Kim SE; Harris WB; Pal SK; Pins MR; Kolesar J; Agarwal N; Parikh RA; Vaena DA; Ryan CW; Hashmi M; Costello BA; Cella D; Dutcher JP; DiPaola RS; Haas NB; Wagner LI; Carducci MA
    J Clin Oncol; 2024 Jun; 42(17):2061-2070. PubMed ID: 38531002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
    Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
    Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
    Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
    JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Randomized Phase III Trial of Adjuvant Pazopanib versus Placebo after Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma.
    Laguna MP
    J Urol; 2018 Jun; 199(6):1393-1394. PubMed ID: 29783587
    [No Abstract]   [Full Text] [Related]  

  • 13. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
    Rexer H
    Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
    [No Abstract]   [Full Text] [Related]  

  • 14. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
    Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
    Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
    Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
    J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.
    Powles T; Sarwar N; Stockdale A; Sarker SJ; Boleti E; Protheroe A; Jones R; Chowdhury S; Peters J; Oades G; O'Brien T; Sullivan M; Aitchison M; Beltran L; Worth D; Smith K; Michel C; Trevisan G; Harvey-Jones E; Wimalasingham A; Sahdev A; Ackerman C; Crabb S
    JAMA Oncol; 2016 Oct; 2(10):1303-1309. PubMed ID: 27254750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Besse B; Mazières J; Ribassin-Majed L; Barlesi F; Bennouna J; Gervais R; Moreau L; Berard H; Debieuvre D; Molinier O; Moro-Sibilot D; Souquet PJ; Jacquot S; Petit L; Lena H; Pignon JP; Lacas B; Morin F; Milleron B; Zalcman G; Soria JC;
    Ann Oncol; 2017 May; 28(5):1078-1083. PubMed ID: 28327934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
    Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
    Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.